SCHEMBL2955707

SCHEMBL2955707

Cc1ccc2c(Nc3cc(Cl)ccc3Oc3ccc(C#N)cc3)ccnc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.41
NR4A2 P43354 1/20 0.40
MAPKAPK2 P49137 2/20 0.39
GCK P35557 1/20 0.39
MAPT P10636 1/20 0.37
GAK O14976 3/20 0.37
RIPK2 O43353 2/20 0.37
COQ8A Q8NI60 2/20 0.37
NLK Q9UBE8 2/20 0.37
EGFR P00533 1/20 0.36
ERBB2 P04626 1/20 0.36
ERBB3 P21860 1/20 0.36
ERBB4 Q15303 1/20 0.36
SCN5A Q14524 2/20 0.36
SCN9A Q15858 2/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
IKBKB O14920 1/20 0.36
KCNH2 Q12809 1/20 0.35
P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955700 0.87 IGF1R (0.45) IGF1RNR4A2MAPKAPK2MAPTGAK
SCHEMBL2968548 0.86 IGF1R (0.42) IGF1RNR4A2MAPKAPK2MAPTGAK
SCHEMBL2970983 0.84 NR4A2 (0.42) IGF1RNR4A2MAPTGAKSCN5A
SCHEMBL2957627 0.83 IGF1R (0.40) IGF1RNR4A2MAPTGAKSCN5A
SCHEMBL2968878 0.82 IGF1R (0.47) IGF1RMAPTPOLBIKBKBMAPK1
SCHEMBL2968819 0.82 IGF1R (0.45) IGF1RNR4A2MAPTSCN9AL3MBTL1
SCHEMBL2961143 0.81 IGF1R (0.40) IGF1RNR4A2MAPTGAKSCN5A
SCHEMBL2968384 0.79 MRGPRX4 (0.49) IGF1RNR4A2POLBP2RX3MAPK1
SCHEMBL2960941 0.79 IGF1R (0.44) IGF1RNR4A2GCKMAPTKCNH2
SCHEMBL2957768 0.79 IGF1R (0.42) IGF1RNR4A2MAPTPOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 IGF1R 4518/4885NR4A2 2293/4885MAPKAPK2 3663/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 IGF1R 4518/4885NR4A2 2293/4885MAPKAPK2 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.